NADAC acquisition cost data for ARIPIPRAZOLE 30 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 16714078801 | $0.2307 | 2022-08-17 | Rx |
| 16714078801 | $0.2307 | 2022-08-17 | Rx |
| 16714078801 | $0.2307 | 2022-08-17 | Rx |
| 00904651404 | $0.2763 | 2022-12-21 | Rx |
| 13668022105 | $0.2763 | 2022-12-21 | Rx |
| 13668022130 | $0.2763 | 2022-12-21 | Rx |
| 13668022190 | $0.2763 | 2022-12-21 | Rx |
| 16714014601 | $0.2763 | 2022-12-21 | Rx |
| 16729028301 | $0.2763 | 2022-12-21 | Rx |
| 16729028310 | $0.2763 | 2022-12-21 | Rx |
Generic: Aripiprazole | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $481.4M | 3,119,178 | 509,862 | $4.26 |
| 2020 | $374.6M | 3,308,604 | 528,325 | $3.00 |
| 2021 | $361.2M | 3,408,021 | 561,796 | $2.75 |
| 2022 | $455.1M | 3,508,453 | 581,092 | $3.31 |
| 2023 | $372.7M | 3,661,359 | 613,179 | $2.57 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $40.8M | 297,693 | 52,198 |
| New York | $28.8M | 272,626 | 41,232 |
| Florida | $24.5M | 225,626 | 46,103 |
| Ohio | $22.7M | 173,112 | 28,658 |
| Pennsylvania | $19.6M | 200,323 | 30,833 |
| Texas | $18.0M | 201,968 | 40,741 |
| Indiana | $13.2M | 83,322 | 15,405 |
| Michigan | $11.0M | 136,332 | 24,245 |
| Massachusetts | $10.9M | 101,923 | 17,045 |
| Missouri | $10.2M | 105,372 | 17,135 |
| New Jersey | $10.1M | 90,444 | 15,105 |
| Illinois | $9.9M | 114,398 | 19,793 |
| Virginia | $9.8M | 73,479 | 14,049 |
| Kentucky | $9.2M | 64,339 | 12,265 |
| Wisconsin | $8.5M | 82,714 | 13,263 |
| North Carolina | $8.5M | 116,176 | 21,668 |
| Tennessee | $8.4M | 90,439 | 17,592 |
| Georgia | $7.9M | 97,000 | 18,111 |
| Minnesota | $7.0M | 76,846 | 11,474 |
| Connecticut | $6.9M | 50,452 | 8,298 |
| Alabama | $6.1M | 58,928 | 11,909 |
| Washington | $6.1M | 71,220 | 12,489 |
| Maryland | $5.2M | 54,441 | 10,078 |
| Arizona | $4.9M | 66,959 | 12,891 |
| Iowa | $4.9M | 48,812 | 7,515 |
| Colorado | $4.1M | 49,108 | 9,110 |
| Oregon | $4.1M | 47,216 | 8,444 |
| South Carolina | $4.1M | 48,783 | 9,799 |
| Louisiana | $3.9M | 59,188 | 11,300 |
| Kansas | $3.9M | 38,993 | 6,548 |
| Oklahoma | $3.8M | 43,699 | 8,800 |
| Arkansas | $3.4M | 45,332 | 8,332 |
| Maine | $3.3M | 20,020 | 3,924 |
| Mississippi | $3.0M | 37,091 | 7,037 |
| Idaho | $2.8M | 23,654 | 4,186 |
| West Virginia | $2.4M | 29,968 | 5,915 |
| Nebraska | $2.3M | 28,469 | 4,280 |
| New Hampshire | $2.1M | 20,423 | 3,517 |
| Utah | $2.0M | 26,106 | 4,982 |
| Rhode Island | $1.9M | 19,025 | 3,199 |
| New Mexico | $1.7M | 18,594 | 3,845 |
| Nevada | $1.7M | 21,035 | 4,634 |
| Vermont | $1.4M | 9,949 | 1,643 |
| Montana | $1.3M | 14,919 | 2,214 |
| Puerto Rico | $1.1M | 42,031 | 5,891 |
| Delaware | $995.6K | 11,957 | 2,365 |
| North Dakota | $983.3K | 11,487 | 1,748 |
| South Dakota | $814.9K | 11,077 | 1,692 |
| Hawaii | $717.0K | 7,442 | 1,538 |
| District of Columbia | $531.2K | 5,910 | 1,392 |
| Alaska | $470.0K | 6,456 | 893 |
| Wyoming | $467.7K | 5,670 | 1,053 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.